Jonathan Hepple

Board Members
Haematology
Clanotech AB
Sweden

Business Expert Haematology
Biography

Jonathan Hepple, Ph D, Venture investor in life science companies since 1998. Founder of Rosetta Capital, a leading international secondary venture firm, focused on life sciences. Rosetta's investments include Enobia Pharmaceuticals, GeminX Pharmaceuticals, Cytochroma, Forward Pharma and Zealand Pharmaceuticals. Also Partner at Seroba Kernel Life Sciences, a European venture firm, investing in biotech and medtech. Current board seats include Axelar AB, Clanotech AB, Covagen AG and Opsona Therapeutics. 

Research Intrest

Haematology